

CITATION REPORT

List of articles citing

Hydroxychloroquine in systemic lupus erythematosus

DOI: 10.1016/s0140-6736(07)60591-1
Lancet, The, 2007, 369, 1257-1258.

Source: <https://exaly.com/paper-pdf/42091100/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al. <i>Arthritis and Rheumatism</i> , 2008 , 59, 153; author reply 153-4		
28	Reply. <i>Arthritis and Rheumatism</i> , 2008 , 59, 153-154		
27	Diagnostic approach and treatment of cutaneous lupus erythematosus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008 , 6, 48-59	1.2	24
26	[Systemic lupus erythematosus from 1968 to 2008: the silent revolution]. <i>Revue De Medecine Interne</i> , 2008 , 29, 689-90	0.1	0
25	Comprehensive geriatric assessment of elderly highlanders in Qinghai, China I: activities of daily living, quality of life and metabolic syndrome. <i>Geriatrics and Gerontology International</i> , 2009 , 9, 333-41	2.9	13
24	Community-based geriatric assessment and preventive intervention lowered medical expenses for the elderly. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 791-3	5.6	1
23	[Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. <i>Revue De Medecine Interne</i> , 2010 , 31, 854-7	0.1	6
22	Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus. <i>Biologics: Targets and Therapy</i> , 2011 , 5, 21-31	4.4	14
21	"Field medicine" for reconsidering "optimal aging". <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 1568-70	5.6	1
20	Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2012 , 14, R155	5.7	148
19	Recommendations for diagnosis and treatment Treatment of systemic lupus erythematosus. Part I. Guidelines for the treatment of systemic lupus erythematosus. <i>Reumatologia</i> , 2012 , 5, 383-389	1.7	1
18	The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. <i>Journal of Neurology</i> , 2012 , 259, 1290-7	5.5	52
17	Adherence to treatment in systemic lupus erythematosus patients. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 329-40	5.3	106
16	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1786-92	2.4	126
15	Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. <i>Autoimmunity</i> , 2013 , 46, 531-6	3	28
14	Special aspects in the treatment of systemic lupus erythematosus. <i>Reumatologia</i> , 2013 , 3, 210-214	1.7	
13	A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis. <i>Lupus</i> , 2014 , 23, 436-42	2.6	9

12	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. <i>Lupus Science and Medicine</i> , 2014 , 1, e000027	4.6	40
11	The course of myasthenia gravis with systemic lupus erythematosus. <i>European Neurology</i> , 2014 , 72, 326-31	2.1	8
10	Glucocorticoid receptor genetic polymorphisms is associated with improvement of health-related quality of life in Chinese population with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2015 , 34, 1537-44	3.9	11
9	Hydroxychloroquine inhibits CD154 expression in CD4 T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. <i>Arthritis Research and Therapy</i> , 2017 , 19, 183	5.7	33
8	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1074-1082	6.1	24
7	Ustekinumab: a promising new drug for SLE?. <i>Lancet, The</i> , 2018 , 392, 1284-1286	4.0	5
6	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 374-382	6.1	20
5	Hydroxychloroquine: balancing the needs of LMICs during the COVID-19 pandemic. <i>Lancet Rheumatology, The</i> , 2020 , 2, e385-e386	14.2	2
4	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020 , 59, 3807-3816	3.9	10
3	Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method. <i>Journal of Separation Science</i> , 2021 ,	3.4	2
2	The combination of hydroxychloroquine and 2-deoxyglucose enhances apoptosis in breast cancer cells by blocking protective autophagy and sustaining endoplasmic reticulum stress. <i>Cell Death Discovery</i> , 2022 , 8,	6.9	4
1	Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. 2023 , 10, e000841		0